mRNA and gene editing: Late breaking therapies in liver diseases

Nerea Zabaleta, Laura Torella, Nicholas D. Weber, Gloria Gonzalez‐Aseguinolaza – 3 March 2022 – The efficient delivery of RNA molecules to restore the expression of a missing or inadequately functioning protein in a target cell and the intentional specific modification of the host genome using engineered nucleases represent therapeutic concepts that are revolutionizing modern medicine.

Ten‐eleven translocation‐2 inactivation restrains IL‐10‐producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma

Zhou Lu, Ronghua Liu, Yining Wang, Mengxia Jiao, Zhongchen Li, Zhiqiang Wang, Cheng Huang, Guoming Shi, Aiwu Ke, Luman Wang, Ying Fu, Jie Xia, Haoyu Wen, Jian Zhou, Xiaoying Wang, Dan Ye, Jia Fan, Yiwei Chu, Jiabin Cai – 3 March 2022

Integrin subunit beta 8 contributes to lenvatinib resistance in HCC

Wei Hou, Bryan Bridgeman, Greg Malnassy, Xianzhong Ding, Scott J. Cotler, Asha Dhanarajan, Wei Qiu – 2 March 2022 – Lenvatinib is a multikinase inhibitor approved as a first‐line therapy for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the underlying mechanisms governing this resistance are largely unknown. In this study, we established two lenvatinib‐resistant (LR) HCC cell lines and identified integrin subunit beta 8 (ITGB8) as a critical contributor to lenvatinib resistance in HCC.

A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis

Elizabeth J. Carey, John Eaton, Mitchell Clayton, Andrea Gossard, Sara Iqbal, Hamid Ullah, Nan Zhang, Richard Butterfield, Keith D. Lindor – 2 March 2022 – The purpose of this pilot study was to explore the efficacy, safety, and tolerability of vidofludimus calcium (VC) in the treatment of primary sclerosing cholangitis (PSC). This was a single‐arm open‐label pilot study with a cohort of 18 patients with PSC. Study patients received VC for a period of 6 months. The study was undertaken at two sites, Mayo Clinic, Rochester, MN, and Mayo Clinic, Phoenix, AZ.

Sarcopenia HIBA score predicts sarcopenia and mortality in patients on the liver transplant waiting list

Ezequiel Mauro, Juan Manuel Diaz, Lucrecia Garcia‐Olveira, Juan Carlos Spina, Lorena Savluk, Fernanda Zalazar, Julia Saidman, Martin De Santibañes, Juan Pekolj, Eduardo De Santibañes, Gonzalo Crespo, Juan G. Abraldes, Adrían Gadano – 2 March 2022 – Sarcopenia is a prevalent condition that predicts prognosis in patients awaiting liver transplantation (LT). The gold standard for the diagnosis of sarcopenia is the assessment of the muscular area at L3 with computed tomography (CT) scan (skeletal muscle index [SMI]), but the routine use of CT scan is limited in clinical practice.

Subscribe to